Paul Sampognaro, MD

Richard Olney Clinician-Scientist Development Award in ALS

University of California, San Francisco

No adequate therapies currently exist to prevent or reverse the motor deficits of amyotrophic lateral sclerosis (ALS). However, mutations in certain genes, including TARDBP, have been identified in some familial cases of ALS, indicating that this gene may be one cause or risk factor of the disease. Dr. Sampognaro’s research will help to clarify the disease mechanism of ALS and identify new therapeutic targets for treatment.

This research is funded by The ALS Association and the American Brain Foundation, in collaboration with the American Academy of Neurology. Dr. Sampognaro will conduct his research at the University of California, San Francisco.